LCTX - Lineage Cell Therapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
3,032
4,988
3,458
5,923
Cost of Revenue
341
302
168
358
Gross Profit
2,691
4,686
3,290
5,565
Operating Expenses
Research Development
18,242
21,755
24,024
36,106
Selling General and Administrative
26,668
24,726
19,922
28,426
Total Operating Expenses
44,910
46,481
43,946
64,532
Operating Income or Loss
-42,219
-41,795
-40,656
-58,967
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-18,716
-6,046
18,059
78,335
Income Before Tax
-59,224
-47,130
-23,289
18,621
Income Tax Expense
-6,969
-346
0
0
Income from Continuing Operations
-52,255
-46,784
-23,289
18,621
Net Income
-52,179
-45,990
-19,976
33,572
Net Income available to common shareholders
-52,179
-45,990
-19,976
33,572
Reported EPS
Basic
-
-0.36
-0.17
0.35
Diluted
-
-0.36
-0.17
0.34
Weighted average shares outstanding
Basic
-
126,903
114,476
97,316
Diluted
-
126,903
114,476
99,553
EBITDA
-
-38,522
-37,360
-58,967